Bristol-Myers Subpoenaed Over Plavix Deal
The request for information from the U.S. Federal Trade Commission was revealed on March 21 in Bristol-Myers Squibb’s annual regulatory filing with the U.S. Securities and Exchange Commission.
The New York-based company said in a statement that it plans to cooperate fully with the investigation. The deal at the center of the probe...
To view the full article, register now.